
From: Denise Lynch
To: Katie Hiatt; Jennifer Clark
Sent: 12/14/2011 1:38:07 PM
Subject: RE: Questions for CDF Audit

Thanks Katie,

This looks great. I would like to add the following:

Is there a way to get to total patients in the fund (what % of the fund is made up of Copaxone patients....I don't believe they can provide this directly but is there some way you can back in to the answer?
What % of patients have reapplied for 2012 assistance? How many are expected to reapply?
Donors to the fund?

Denise C. Lynch

Sr. Director, Patient Services and Support

Teva Neuroscience

901 E. 104th St., Suite 900

Kansas City, MO 64131

Phone: (816) 508-5139 Fax: (816) 508-5508

Email: denise.lynch@tevapharm.com

From: Katie Hiatt
Sent: Tuesday, December 13, 2011 4:00 PM
To: Denise Lynch; Jennifer Clark
Subject: Questions for CDF Audit

Denise & Jennifer,

Below is the list of items I believe we want addressed in the audit with Chronic Disease Fund. Please review and let me know if you want to make changes or additions:

- Count on LIS or partial LIS patients, if any
- Discrete patients who received assistance last year
- Scripts vs patients..looking for number of fills
- Pharmacy placement..ie who is at ACS and other pharmacies
- How much rollover money do we have
- Have all funds been returned back to the general fund that were not used at the patient level

Regards,



Katie Hiatt Dir. Finance & Planning

Tel: (816) 508-5088 Cell: (913) 709-0507 Fax: (913) 508-5592

Katie.Hiatt@tevapharm.com sip:Katie.Hiatt@tevapharm.com www.tevapharm.com